News

Antihistamine drug chlorcyclizine shows promise for treating HCV


 

References

Repurposing the antihistamine medication chlorcyclizine may be a viable option in the treatment of hepatitis C, reported Dr. Shanshan He and coauthors.

In a study of mice carrying human hepatocytes infected with hepatitis C virus, chlorcyclizine significantly inhibited infection of HCV genotypes 1b and 2a without drug resistance at 4 and 6 weeks of treatment (P < .05), respectively, Dr. He and associates reported.

The findings suggest that the use of chlorcyclizine in treating HCV infection may “provide a more affordable alternative to the current costly options, especially in low-resource settings where chronic HCV infection is endemic,” the investigators said in the paper.

Read the full article in Science Translational Medicine 2015 at: doi/10.1126/scitranslmed.3010286.

Recommended Reading

Study found two-way link between IBD and cervical cancer
MDedge Internal Medicine
Two-thirds of endoscopists met colonic adenoma detection benchmarks
MDedge Internal Medicine
Four genes linked to phenotypic traits of Crohn’s disease
MDedge Internal Medicine
All-oral simeprevir-sofosbuvir beat interferon-based regimen for HCV with compensated cirrhosis
MDedge Internal Medicine
‘Tailored navigation’ ups colorectal cancer screening adherence
MDedge Internal Medicine
Colonoscopy follow-up varied widely after positive fecal blood test
MDedge Internal Medicine
New hepatitis treatment cost effective for some patient types
MDedge Internal Medicine
Add baseline DHEAS when screening adrenal incidentalomas for subclinical hypercortisolism
MDedge Internal Medicine
United States experiencing drug-resistant shigellosis outbreak
MDedge Internal Medicine
No increased risk of lung disease with methotrexate
MDedge Internal Medicine